In 2017, Indivior PLC received the U.S. Food and Drug Administration (FDA) approval for its new SUBLOCADE (buprenorphine extended- release) injection for subcutaneous use. SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder. In 2016, Teva Pharmaceutical Industries Ltd. launched a generic version of CAMPRAL1 (acamprosate calcium) delayed-release tablets, 333 mg in the U.S. market. This tablet is indicated for the treatment and maintenance of abstinence from alcohol in patients with alcohol dependence.

Click To Continue Reading On Drug Abuse Treatment Market

In April 2018, Dr. Reddy's Laboratories received the U.S. Food and Drug Administration (FDA) approval to launch generic version of Suboxone sublingual film indicated for the treatment of drug addiction. Suboxone is a combination of Buprenorphine and Naloxone, Dr. Reddy's Laboratories received approval for all dosage forms 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg.

In 2014, British American Tobacco plc. received approval from the UK Medicines and Healthcare products regulatory agency for new products nicotine inhaler. This new inhaler will help to quit smoking habits of addicted smokers, this new inhaler contains the same propellant found in an asthma inhaler and gives an immediate hit of nicotine through a breath-operated valve. In 2015 company launched nicotine inhaler in the UK. Frequent launches of such novel drugs in market are expected to fuel the global drug abuse treatment market growth.

The global drug abuse treatment market size was valued at US$ 13.4 Bn in 2017, and is expected to witness a CAGR of 7.8% over the forecast period (2018 – 2026).

Get The Holistic SAMPLE With Research Methodology:

https://www.coherentmarketinsights.com/insight/request-sample/2011

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]

Visit our news Website: https://www.coherenttimes.org